2018年美国心脏协会心肺复苏与心血管急救指南更新解读——儿童高级生命支持  

Interpretation of the 2018 Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: pediatric advanced life support

作　　者：周艳[1] 李熙鸿[1] ZHOU Yan;LI Xihong(Department of Emergency Medicine,West China Second University Hospital,Sichuan University / Key Laboratory of Birth Defects and Related Diseases of Women and Children,Ministry of Educatio;Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西第二医院急诊医学科/出生缺陷与相关妇儿疾病教育部实验室,成都610041

出　　处：《华西医学》2018年第11期1356-1358,共3页West China Medical Journal

摘　　要：2018年11月美国心脏协会更新了心肺复苏与心血管急救指南。此次更新再次践行了"指南只要有新证据将及时更新"的原则,对儿童电击除颤难以纠正的心室颤动/无脉性室性心动过速的抗心律失常药物治疗进行了证据回顾并提出治疗建议,并非对2015版指南进行全面修订。更新由国际复苏联络委员会儿科工作组完成,重申了2015年儿童高级生命支持指南推荐,以及儿童电击除颤难以纠正的心室颤动/无脉性室性心动过速可使用抗心律失常药物利多卡因或胺碘酮治疗。In November 2018, the American Heart Association （AHA） updated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Rather than a comprehensive revision of the 2015 edition guidelines, the 2018 AHA guidelines update was updated again according to the rule ＂the update of the guideline is whenever new evidence is available＂, providing the evidence review and treatment recommendation for antiarrhythmic drug therapy in pediatric shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. The Pediatric Task Force of the International Liaison Committee on Resuscitation updated the guideline, reaffirming the 2015 pediatric advanced life support guideline recommendation that either lidocaine or amiodarone may be used to treat pediatric patients with shock-refractory ventricular fibrillation or pulseless ventricular tachycardia.

关 键 词：美国心脏协会 高级生命支持 指南 儿童 抗心律失常药物治疗 

分 类 号：R720.597[医药卫生—急诊医学]